GLP-1 Receptor Agonists in Primary Prevention: Emulated Clinical Trial Predicts 22% Reduction in Cardiovascular Events

Highlights

The study emulated the use of GLP-1 receptor agonists (GLP-1RAs) for primary cardiovascular prevention in a large cohort of over 600,000 individuals. For obese individuals with a high baseline risk (SCORE2 ≥7.5%), the therapy was projected to lower the 10-year cardiovascular disease (CVD) incidence from 13.82% to 10.83%. This represents a significant 22% relative risk reduction and a 2.99% absolute risk reduction, with slightly higher absolute benefits observed in men compared to women.

Introduction: The Evolution of GLP-1 Receptor Agonists